Xlife Sciences AG (FRA:XLS) Other Financing: €3.16 Mil (TTM As of Dec. 2025)


FRA:XLS Xlife Sciences AG FRA:XLS
56 GF Score
Price €21.60
GF Value €7.80
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG Other Financing?

Xlife Sciences AG FRA:XLS -2.70% 56 Other Financing is €3.16 Mil as of Dec. 2025. GuruFocus rates FRA:XLS with a GF Score™ of 56/100 and a GF Value™ of €7.80 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Xlife Sciences AG's Other Financing for the six months ended in Dec. 2025 was €3.16 Mil.

Xlife Sciences AG's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was €3.16 Mil.

Xlife Sciences AG Other Financing Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG Other Financing Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial -0.70 -0.35 -0.01 -0.12 -0.12

Xlife Sciences AG Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 -0.00 -0.12 0.00 3.16
FRA:XLS
56GF Score
Xlife Sciences AG FRA:XLS
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xlife Sciences AG Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €3.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €3.16 Mil mean?
Xlife Sciences AG (FRA:XLS) has a Other Financing of €3.16 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's Other Financing too high?
Xlife Sciences AG's current Other Financing is €3.16 Mil. Overall, Xlife Sciences AG has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Other Financing compare to VRTX and REGN?
Xlife Sciences AG's Other Financing of €3.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Xlife Sciences AG and its competitors. Xlife Sciences AG's current Other Financing is €3.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (FRA:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.80, compared to a current price of €21.60 — trading 176.9% above its estimated fair value. The current Other Financing is €3.16 Mil. Xlife Sciences AG's overall GF Score™ is 56/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Xlife Sciences AG (FRA:XLS), the current Other Financing is €3.16 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (FRA:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of €21.60 is trading 176.9% above its estimated GF Value™ of €7.80. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for FRA:XLS:

  • Other Financing: €3.16 Mil
  • GF Value™: €7.80 vs. price of €21.60 (176.9% above fair value)
  • GF Score™: 56/100 with 10 warning signs

No single metric tells the full story. See the FRA:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Switzerland
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
56GF Score

Get the complete analysis for FRA:XLS

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.60
Price
€7.80
GF Value